WO1995024919A1 - Nouvelle utilisation d'hormones de croissance - Google Patents

Nouvelle utilisation d'hormones de croissance Download PDF

Info

Publication number
WO1995024919A1
WO1995024919A1 PCT/BE1995/000022 BE9500022W WO9524919A1 WO 1995024919 A1 WO1995024919 A1 WO 1995024919A1 BE 9500022 W BE9500022 W BE 9500022W WO 9524919 A1 WO9524919 A1 WO 9524919A1
Authority
WO
WIPO (PCT)
Prior art keywords
growth hormone
low
patient
level
dopamine
Prior art date
Application number
PCT/BE1995/000022
Other languages
English (en)
Inventor
Greta Herman Van Den Berghe
Francis Edouard De Zegher
Original Assignee
K.U. Leuven Research & Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NL9401045A external-priority patent/NL9401045A/nl
Application filed by K.U. Leuven Research & Development filed Critical K.U. Leuven Research & Development
Priority to AU19429/95A priority Critical patent/AU1942995A/en
Publication of WO1995024919A1 publication Critical patent/WO1995024919A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelle utilisation d'hormones de croissance, par exemple d'hormones de croissance recombinées et de préférence humaines, dans la fabrication d'une préparation pharmaceutique destinée au traitement des malades souffrant d'un faible taux de triiodothyronine. Un faible taux de triiodothyronine peut résulter du syndrome du faible taux de T3 tel que décrit dans la littérature. Le syndrome du faible taux de T3 chez un malade peut être dû à différentes affections cliniques tant physiques que mentales. La consommation de médicaments peut également entraîner le syndrome du faible taux de T3. Selon l'invention, on peut administrer au moins une hormone thyroïdienne et/ou au moins un stéroïde anabolisant en même temps que l'hormone de croissance.
PCT/BE1995/000022 1994-03-15 1995-03-15 Nouvelle utilisation d'hormones de croissance WO1995024919A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19429/95A AU1942995A (en) 1994-03-15 1995-03-15 New use of growth hormone

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94200661.0 1994-03-15
EP94200661 1994-03-15
NL9401045A NL9401045A (nl) 1994-03-15 1994-06-24 Nieuw gebruik van groeihormoon.
NL9401045 1994-06-24

Publications (1)

Publication Number Publication Date
WO1995024919A1 true WO1995024919A1 (fr) 1995-09-21

Family

ID=26136095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BE1995/000022 WO1995024919A1 (fr) 1994-03-15 1995-03-15 Nouvelle utilisation d'hormones de croissance

Country Status (2)

Country Link
AU (1) AU1942995A (fr)
WO (1) WO1995024919A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001152A1 (fr) 1996-07-10 1998-01-15 Sumitomo Pharmaceuticals Company, Limited Medicaments pour les troubles alimentaires
WO2003092725A1 (fr) * 2002-05-03 2003-11-13 Metabolic Pharmaceuticals Limited Procede permettant de maitriser la depression a l'aide d'un fragment d'hormone de croissance (gh) a terminaison c
WO2004026330A1 (fr) * 2002-09-23 2004-04-01 K.U. Leuven Research And Development Methodes et preparations permettant de soigner des patients en phase critique
EP1806131A3 (fr) * 1996-07-22 2007-08-01 Renovo Limited Utilisation de modulateurs de la fonction stéroïde sexuelle pour traiter des plaies et des troubles fibrogènes
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009189A1 (fr) * 1989-02-07 1990-08-23 Brigham And Women's Hospital Traitement du dysfonctionnement pulmonaire et de la dependance vis-a-vis d'un ventilateur a l'aide d'une hormone de croissance
WO1991011196A1 (fr) * 1990-02-02 1991-08-08 Novo Nordisk A/S Procede de traitement pour mammiferes utilisant un compose biologiquement actif
WO1993004694A1 (fr) * 1991-09-05 1993-03-18 Novo Nordisk A/S Methode de traitement des malades atteints de maladies de foie chroniques
WO1995000167A1 (fr) * 1993-06-25 1995-01-05 Pharmacia Ab Utilisation de l'hormone de croissance humaine en administration preoperatoire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990009189A1 (fr) * 1989-02-07 1990-08-23 Brigham And Women's Hospital Traitement du dysfonctionnement pulmonaire et de la dependance vis-a-vis d'un ventilateur a l'aide d'une hormone de croissance
WO1991011196A1 (fr) * 1990-02-02 1991-08-08 Novo Nordisk A/S Procede de traitement pour mammiferes utilisant un compose biologiquement actif
WO1993004694A1 (fr) * 1991-09-05 1993-03-18 Novo Nordisk A/S Methode de traitement des malades atteints de maladies de foie chroniques
WO1995000167A1 (fr) * 1993-06-25 1995-01-05 Pharmacia Ab Utilisation de l'hormone de croissance humaine en administration preoperatoire

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001152A1 (fr) 1996-07-10 1998-01-15 Sumitomo Pharmaceuticals Company, Limited Medicaments pour les troubles alimentaires
EP0916345A1 (fr) * 1996-07-10 1999-05-19 Sumitomo Pharmaceuticals Company, Limited Medicaments pour les troubles alimentaires
EP0916345A4 (fr) * 1996-07-10 2008-08-06 Dainippon Sumitomo Pharma Co Medicaments pour les troubles alimentaires
EP1806131A3 (fr) * 1996-07-22 2007-08-01 Renovo Limited Utilisation de modulateurs de la fonction stéroïde sexuelle pour traiter des plaies et des troubles fibrogènes
WO2003092725A1 (fr) * 2002-05-03 2003-11-13 Metabolic Pharmaceuticals Limited Procede permettant de maitriser la depression a l'aide d'un fragment d'hormone de croissance (gh) a terminaison c
WO2004026330A1 (fr) * 2002-09-23 2004-04-01 K.U. Leuven Research And Development Methodes et preparations permettant de soigner des patients en phase critique
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
US10130643B2 (en) 2005-05-26 2018-11-20 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US10925885B2 (en) 2005-05-26 2021-02-23 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US11202789B2 (en) 2016-11-21 2021-12-21 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Also Published As

Publication number Publication date
AU1942995A (en) 1995-10-03

Similar Documents

Publication Publication Date Title
Theobald et al. Use of post-pituitary extract in obstetrics
Walker et al. Pseudotumor cerebri associated with prolonged corticosteroid therapy: reports of four cases
WO1995024919A1 (fr) Nouvelle utilisation d'hormones de croissance
US4477434A (en) Medicinal compositions, foods and beverages having therapeutic effects on diseases of circulatory system and digestive system
Byrne et al. Home total parenteral nutrition: an alternative approach to the management of children with severe chronic small bowel disease
JP2003252765A (ja) 腸管運動機能不全性疾患の治療剤
Greenwood Lumbar plexitis and rhabdomyolysis following abuse of heroin
Keech et al. Anterior segment ischemia following vertical muscle transposition and botulinum toxin injection
Tasker et al. Non-ketotic diabetic precoma associated with high-dose frusemide therapy.
Merrill Present role of the artificial kidney in clinical therapy
Ellman et al. Osteomalacia following gastrectomy
Adams et al. Postoperative acute adrenal cortical insufficiency
Reid et al. The treatment of the vomiting of early pregnancy
Kersley et al. Hypoglycaemia in treatment of rheumatoid arthritis
HENDERSON et al. Androgens and Renal Function. Effect of Testosterone Propionate in Uremia due to Cholera
PT98764B (pt) Processo para a preparacao de composicoes contendo factor de desenvolvimento de insulina 1 completo para o tratamento terapeutico ou profilactico de estado catabolicos
RU2716144C1 (ru) Способ консервативного лечения послеоперационного пареза кишечника у новорожденных детей
Shipton, EA & Muller Severe mefenamic acid poisoning-a case report
SU1268171A1 (ru) Способ профилактики острой адренокортикальной недостаточности при хирургических операци х
NL9401045A (nl) Nieuw gebruik van groeihormoon.
RU2314794C2 (ru) Способ лечения наркомании и/или алкоголизма и дозирующая система для его осуществления
Gibbs Pseudotumours of the orbit.
Jones Medical and Surgical Treatment of Peptic Ulcer
Marks et al. Effect of preoperative isotonic expansion of extracellular fluid volume on postoperative renal sodium excretion
Schrire, T. & Schrire Surgery in the aged

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase